KZR-261 is under clinical development by Kezar Life Sciences and currently in Phase I for Castration-Resistant Prostate Cancer (CRPC). According to GlobalData, Phase I drugs for Castration-Resistant Prostate Cancer (CRPC) have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how KZR-261’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
KZR-261 overview
KZR-261 is under development for the treatment of solid tumors including prostate cancer, castrate resistant prostate cancer, colorectal cancer, mesothelioma, melanoma and uveal melanoma, small cell lung cancer (SCLC) and hematological malignancies including mantle cell lymphoma (MCL). The drug candidate is protein secretion modulators that act by targeting Sec61. It is administered through intravenous route.
Kezar Life Sciences overview
Kezar Life Sciences is a clinical-stage biotechnology company. It discovers and develops small molecule therapies to treat autoimmunity and cancer. The company offers products such as KZR-616 and KZR-261. KZR-261 focusses in the treatment of various autoimmune diseases, lupus nephritis, solid tumors, oncology, immunology and idiopathic inflammatory myopathies. Kezar Life Sciences’ product KZR-616 is a selective immunoproteasome inhibitor used for the treatment of chronic immune-mediated diseases. It offers clinical trial services. The company also discovers and develops targeted cancer and immuno-oncology indications. Kezar Life Sciences is headquartered in South San Francisco, California, the US.
For a complete picture of KZR-261’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.